Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Douglas  Johnson

Douglas Johnson, M.D., M.S.C.I.

Assistant Professor of Medicine
Clinical Director, Melanoma
Medical Oncologist

  • Appointments
    615-935-8422
    Physicians: 1-877-936-8422
  • Clinical Trials Information
  • Other Telephone Numbers
    Division of Hematology/Oncology
    (615) 322-4967

    Henry-Joyce Cancer Clinic
    (615) 936-8422 or 1 (877) 936-8422

    Office
    615-936-3524
  • Faxes
    Division of Hematology/Oncology Fax
    (615) 343-7602
    Henry-Joyce Cancer Clinic Fax
    (615) 343-8668
    Office Fax
    615-343-7602
  • Addresses
    Clinic
    1301 Medical Center Drive
    1710 The Vanderbilt Clinic
    Nashville, TN 37232

    Division of Hematology/Oncology
    2220 Pierce Ave, 777 PRB
    Nashville, TN 37232-6307
    Website

    Henry-Joyce Cancer Clinic
    1301 Medical Center Drive, Suite 1710
    Nashville, Tennessee 37232-7415
    Website

    Office
    777 Preston Research Building
    2220 Pierce Avenue
    Nashville, TN 37232
Profile

Dr. Johnson is a medical oncologist specializing in melanoma skin cancer. After receiving his MD from University of Alabama at Birmingham, he completed residency at Duke University followed by fellowship at Vanderbilt. He is also a graduate of the Master of Science in Clinical Investigation Program at Vanderbilt.
Read more...

Dr. Johnson is a medical oncologist specializing in melanoma skin cancer. After receiving his MD from University of Alabama at Birmingham, he completed residency at Duke University followed by fellowship at Vanderbilt. He is also a graduate of the Master of Science in Clinical Investigation Program at Vanderbilt.

Dr. Johnson leads the melanoma clinical research program at Vanderbilt. His research interests cover a wide range of developing new immune and targeted therapies for melanoma, and in using existing treatments in the most effective ways. Specifically, he is exploring ways to profile cancers to predict which patients will benefit from immune therapies, and has published numerous papers in this area. He is also focused on understanding the effectiveness and toxicities of immune therapies in high risk patients, including those with autoimmune disorders, advanced age, or organ dysfunction. Dr. Johnson is the lead investigator on numerous clinical trials at Vanderbilt.

Education
  • M.D., University of Alabama at Birmingham
  • Residency, Duke University
  • Fellowship, Vanderbilt University
  • M.S.C.I., Vanderbilt University